169 related articles for article (PubMed ID: 12950025)
1. Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping.
Zaffaroni N; De Polo D; Villa R; Della Porta C; Collini P; Fabbri A; Pilotti S; Daidone MG
J Pathol; 2003 Sep; 201(1):127-33. PubMed ID: 12950025
[TBL] [Abstract][Full Text] [Related]
2. Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.
Wang DG; Johnston CF; Sloan JM; Buchanan KD
J Pathol; 1998 Mar; 184(3):247-51. PubMed ID: 9614375
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors.
Brambilla E; Negoescu A; Gazzeri S; Lantuejoul S; Moro D; Brambilla C; Coll JL
Am J Pathol; 1996 Dec; 149(6):1941-52. PubMed ID: 8952529
[TBL] [Abstract][Full Text] [Related]
4. A comparison of NSP-reticulons with conventional neuroendocrine markers in immunophenotyping of lung cancers.
Senden NH; Timmer ED; de Bruïne A; Wagenaar SS; Van de Velde HJ; Roebroek AJ; Van de Ven WJ; Broers JL; Ramaekers FC
J Pathol; 1997 May; 182(1):13-21. PubMed ID: 9227337
[TBL] [Abstract][Full Text] [Related]
5. The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung.
Jiang SX; Kameya T; Shinada J; Yoshimura H
Mod Pathol; 1999 Apr; 12(4):362-9. PubMed ID: 10229500
[TBL] [Abstract][Full Text] [Related]
6. Lack of telomerase activity in lung carcinoids is dependent on human telomerase reverse transcriptase transcription and alternative splicing and is associated with long telomeres.
Zaffaroni N; Villa R; Pastorino U; Cirincione R; Incarbone M; Alloisio M; Curto M; Pilotti S; Daidone MG
Clin Cancer Res; 2005 Apr; 11(8):2832-9. PubMed ID: 15837730
[TBL] [Abstract][Full Text] [Related]
7. Differential retinoblastoma and p16(INK4A) protein expression in neuroendocrine tumors of the lung.
Dosaka-Akita H; Cagle PT; Hiroumi H; Fujita M; Yamashita M; Sharma A; Kawakami Y; Benedict WF
Cancer; 2000 Feb; 88(3):550-6. PubMed ID: 10649246
[TBL] [Abstract][Full Text] [Related]
8. [Detection of telomerase activity level in human non-small-cell lung cancer].
Yang HZ; Hu CP; Su XL
Hunan Yi Ke Da Xue Xue Bao; 2001 Dec; 26(6):549-50. PubMed ID: 12536537
[TBL] [Abstract][Full Text] [Related]
9. Analysis of mutant p53 and telomerase activity in non-small cell lung cancer.
Kiyooka K; Maniwa Y; Okada M
Ann Thorac Cardiovasc Surg; 1999 Oct; 5(5):293-9. PubMed ID: 10550714
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in lung cancer.
Carey FA; Save VE
J Pathol; 1997 May; 182(1):9-10. PubMed ID: 9227335
[TBL] [Abstract][Full Text] [Related]
11. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours.
Kasprzak A; Olejniczak K; Przybyszewska W; Zabel M
Folia Morphol (Warsz); 2007 Aug; 66(3):159-66. PubMed ID: 17985312
[TBL] [Abstract][Full Text] [Related]
12. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Iijima H; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Pathol Res Pract; 2008; 204(8):553-61. PubMed ID: 18440724
[TBL] [Abstract][Full Text] [Related]
13. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.
Folpe AL; Gown AM; Lamps LW; Garcia R; Dail DH; Zarbo RJ; Schmidt RA
Mod Pathol; 1999 Jan; 12(1):5-8. PubMed ID: 9950155
[TBL] [Abstract][Full Text] [Related]
14. LKB1 protein expression in neuroendocrine tumors of the lung.
Amin RM; Hiroshima K; Iyoda A; Hoshi K; Honma K; Kuroki M; Kokubo T; Fujisawa T; Miyagi Y; Nakatani Y
Pathol Int; 2008 Feb; 58(2):84-8. PubMed ID: 18199157
[TBL] [Abstract][Full Text] [Related]
15. Increased human telomerase reverse transcriptase (hTERT) mRNA expression but not telomerase activity is related to survival in curatively resected non-small cell lung cancer.
Metzger R; Vallbohmer D; Müller-Tidow C; Higashi H; Bollschweiler E; Warnecke-Eberz U; Brabender J; Baldus SE; Xi H; Berdel WE; Serve H; Hoelscher AH; Schneider PM
Anticancer Res; 2009 Apr; 29(4):1157-62. PubMed ID: 19414359
[TBL] [Abstract][Full Text] [Related]
16. Telomere length, telomerase activity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pulmonary neuroendocrine tumors.
Nishio Y; Nakanishi K; Ozeki Y; Jiang SX; Kameya T; Hebisawa A; Mukai M; Travis WD; Franks TJ; Kawai T
Jpn J Clin Oncol; 2007 Jan; 37(1):16-22. PubMed ID: 17060405
[TBL] [Abstract][Full Text] [Related]
17. Telomerase activity in endoscopically visible lung cancer.
Hirashima T; Yoshitaka O; Nitta T; Sasada S; Kobayashi M; Masuda N; Matsui K; Nakagawa K; Yasumitsu T; Takada Y; Kikui M; Kawase I
Anticancer Res; 2001; 21(5):3685-9. PubMed ID: 11848543
[TBL] [Abstract][Full Text] [Related]
18. Is small cell lung cancer the perfect target for anti-telomerase treatment?
Sarvesvaran J; Going JJ; Milroy R; Kaye SB; Keith WN
Carcinogenesis; 1999 Aug; 20(8):1649-51. PubMed ID: 10426823
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
20. Biology and novel therapeutics for neuroendocrine tumors of the lung.
Jafri N; Salgia R
J Biol Regul Homeost Agents; 2004; 18(3-4):275-90. PubMed ID: 15786694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
